NCT07732244

Brief Summary

The wireless NIRS sensor will be placed on the participant's forehead, directly underneath the INVOS wired sensor. The wireless NIRS sensor will remain in place for 4 consecutive hours, over 2 consecutive days. As standard-of-care, nursing personnel removes all sensors at every care to evaluate skin and reduce the risk of pressure sores. The wireless NIRS device will be removed and reapplied at the same time, by the research team who will annotate what time the sensor was removed, replaced, and the condition of the skin. This will be used to correlate signal disconnection with sensor care (i.e., skin checks, sensor removal, etc.).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
4mo left

Started Nov 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress68%
Nov 2025Dec 2026

Study Start

First participant enrolled

November 15, 2025

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

May 5, 2026

Completed
3 months until next milestone

First Posted

Study publicly available on registry

July 28, 2026

Completed
4 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2026

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Expected
Last Updated

July 28, 2026

Status Verified

July 1, 2026

Enrollment Period

9 months

First QC Date

May 5, 2026

Last Update Submit

July 27, 2026

Conditions

Keywords

NIRSNear-Infrared SpectroscopyWireless SensorTechnologyNICU

Outcome Measures

Primary Outcomes (1)

  • Comparison of rStO2, data between the wireless NIRS and gold-standard wired NIRS.

    Comparison of rStO2, data between the wireless NIRS and gold-standard wired NIRS.

    6 months

Secondary Outcomes (3)

  • Comparison of SpO2 and Heart Rate (HR) data between the wireless NIRS and gold-standard wired vital sign monitoring system (Philips IntelliVue MX800).

    6 months

  • Comparison of derived Heart Rate Variability (HRV) between the wireless NIRS and gold-standard wired vital sign monitoring system (Philips IntelliVue MX800).

    6 months

  • Provide a questionnaire to capture the perspectives of clinicians and patients' parents/guardians regarding use of the wireless NIRS compared to wired NIRS device.

    6 months

Study Arms (1)

Wireless Near-infrared spectroscopy (NIRS)

OTHER

Wireless NIRS applied to participant's forehead.

Device: Wireless NIRS

Interventions

Wireless NIRS applied to participant forehead.

Wireless Near-infrared spectroscopy (NIRS)

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Infants admitted to the NICU with a gestational age of ≥ 32 weeks at the time of the monitoring
  • undergoing monitoring with the INVOS wired NIRS system.

You may not qualify if:

  • Infants with a skin abnormality that would potentially increase the risk of injury,
  • Patient too unstable or family experiencing too much stress as determined by an attending physician or bedside care team to not be approached for recruitment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Montreal Children's Hospital

Montreal, Quebec, H3H2R9, Canada

RECRUITING

MeSH Terms

Conditions

Hypoxia-Ischemia, BrainHeart Defects, CongenitalHemorrhagic StrokeIntracranial Aneurysm

Condition Hierarchy (Ancestors)

Brain IschemiaCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesHypoxia, BrainVascular DiseasesCardiovascular DiseasesHypoxiaSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and SymptomsCardiovascular AbnormalitiesHeart DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesStrokeIntracranial Arterial DiseasesAneurysm

Study Officials

  • Guilherme Sant'Anna, MD, PhD

    RI-MUHC

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Alyssa Maximov, BSc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Neonatologist

Study Record Dates

First Submitted

May 5, 2026

First Posted

July 28, 2026

Study Start

November 15, 2025

Primary Completion

August 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

July 28, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share

Locations